Clinical Trial Update: CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of CAR T cell therapy targeting mesothelin in metastatic cancer shows terminated status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Lung Cancer
• Mesothelioma
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• CAR T cell receptor immunotherapy targeting mesothelin

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cervical Cancer, Pancreatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-10-09